Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + CP-506 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CP-506 | CP 506|CP506 | Chemotherapy - Alkylating 18 | CP-506 is a DNA alkylating hypoxia-activated prodrug, which potentially induces cytotoxicity in tumor cells under hypoxic conditions and inhibits tumor growth (PMID: 34625504). | |
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04954599 | Phase Ib/II | CP-506 CP-506 + Ipilimumab Carboplatin + CP-506 Cemiplimab + CP-506 CP-506 + Durvalumab CP-506 + Pembrolizumab CP-506 + Nivolumab Avelumab + CP-506 Atezolizumab + CP-506 | Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | Recruiting | NLD | BEL | 0 |